Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,472 total articles
PolyPid Ltd. has initiated the NDA submission to the FDA for its lead product candidate D-PLEX100, aimed at preventing surgical site infections in colorectal surgery patients. The company expects to complete the submission imminently and is in late-stage discussions for a US commercial partnership. New Phase 3 data presented support the drug's clin…
Nexxen announced that it has expanded the Nexxen TV Home Screen platform by integrating TCL FFALCON and TiVo Ads' native Smart TV inventory into its programmatic demand-side platform (DSP). This provides advertisers with premium, high-visibility advertising placements on Smart TV home screens across the U.S., Canada, UK, and globally, enhancing acc…
Nexxen International Ltd. delivered record Q1 2026 financial results including strong growth in Contribution ex-TAC, programmatic revenue, and CTV revenue. The company raised its full-year 2026 revenue guidance driven by broad strength across programmatic business lines and accelerated adoption of its Nexxen TV Home Screen. Continued investments in…
Tower Semiconductor announced the signing of customer contracts valued at $1.3 billion for silicon photonics revenue in 2027, accompanied by $290 million in customer prepayments for capacity reservation. The company is expanding its multi-fab capacity to meet the growing demand driven by AI infrastructure and data center bandwidth needs. Tower targ…
Altimmune, Inc. announced that its IMPACT Phase 2b trial analyzing pemvidutide's efficacy and safety in treating metabolic dysfunction-associated steatohepatitis (MASH) will be presented in oral and poster sessions at the EASL Congress 2026. The 48-week results include positive outcomes such as fibrosis regression, improved liver inflammation and f…
Vishay Intertechnology posted Q1 2026 revenues of $839.2M, with a gross margin of 21.0% and GAAP EPS of $0.05. The company saw a strong book-to-bill ratio of 1.34 and backlog of 5.7 months, reflecting increased customer demand. Management reaffirmed growth strategy focusing on capacity expansion and backlog turn acceleration to maintain short lead …
Milestone Pharmaceuticals announced first quarter 2026 financial results highlighting the successful commercial launch of CARDAMYST nasal spray for PSVT, achieving approximately 600 prescriptions and coverage for over 25% of U.S. commercially insured lives via Express Scripts. The company commenced a Phase 3 pivotal trial for etripamil in atrial fi…
Gilat Satellite Networks Ltd. reported a 20% revenue increase in Q1 2026 to $110.5 million and turned a GAAP operating loss in Q1 2025 into a $4.4 million GAAP operating income this quarter. Adjusted EBITDA doubled to $15.1 million. The company reaffirmed its 2026 guidance with an expected revenue growth of approximately 13% and adjusted EBITDA gro…
Nexentis Technologies, through its subsidiary MitoCareX Bio, has achieved a significant drug discovery milestone by optimizing a hit molecule targeting mitochondrial SLC25 carrier proteins, which are involved in difficult-to-treat cancers and inflammatory metabolic diseases. The milestone validates the MITOLINE® platform's capability to overcome st…
Ocugen, Inc., a NASDAQ-listed biotechnology company specializing in gene therapies for blindness diseases, announced it will participate in key scientific and investor conferences in May 2026 to present its innovative modifier gene therapy platform targeting inherited retinal diseases. The company aims to highlight its gene-agnostic approach that a…
Avalo Therapeutics reported positive topline results from its Phase 2 LOTUS trial of abdakibart for moderate to severe hidradenitis suppurativa (HS), achieving statistically significant improvements in multiple clinical endpoints. The company plans to advance abdakibart into a registrational Phase 3 program. Additionally, Avalo completed a public e…
Anfield Energy Inc. has successfully completed drilling monitoring wells at its Shootaring Canyon Mill in Utah and Slick Rock Mine Complex in Colorado. This development supports environmental oversight and operational readiness as the company advances its hub-and-spoke strategy to restart and expand uranium and vanadium production. The announcement…
Highlander Silver Corp. announced the appointment of Ms. Poonam Puri, an expert in corporate law and governance, to its Board of Directors as an independent director. Ms. Puri brings vast experience that will aid the company in accelerating development across its high-quality silver assets portfolio, including projects in Peru and Mexico.
BeyondSpring Inc. announced its Q1 2026 financial results alongside significant clinical and scientific advancements. Key progress includes Plinabulin demonstrating potential as a backbone therapy enhancing efficacy and tolerability in ADC-based cancer treatments, supported by promising AACR 2026 data. Additionally, SEED Therapeutics, a biotech com…
Seer, Inc., a Nasdaq-listed company specializing in deep proteomic insights, has filed a patent infringement lawsuit against Nanomics Biotechnology, asserting that Nanomics' products infringe on several of Seer's U.S. patents related to nanoparticle protein enrichment. The company emphasizes the strength and robustness of its intellectual property …
Colliers International Group Inc. has initiated a new normal course issuer bid (NCIB) enabling the company to repurchase up to 4.3 million subordinate voting shares, approximately 10% of its public float, from May 2026 to May 2027. This move reflects Colliers’ confidence in its share value and commitment to enhancing shareholder value. All repurcha…
Upstream Bio reported first quarter 2026 financial results and significant progress in its clinical development programs targeting severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD) with its investigational drug verekitug. The company plans Phase 3 trial initiations for severe asthma a…
Lightbridge Corporation and Studsvik Scandpower have formed a partnership to develop an advanced software extension for modeling Lightbridge's next-generation metallic nuclear fuel design. This collaboration aims to support the licensing and commercial deployment of Lightbridge Fuel in light water reactors, promising improvements in safety, economi…
CTW reported a 1% decline in revenue to $40.9 million for the first half of fiscal 2026 compared to the prior year period. Despite modest revenue softness due to underperformance of new game launches and lifecycle trends in legacy titles, the company achieved a 55% increase in segment profit and 16% rise in Adjusted EBITDA by optimizing marketing s…
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing novel FASN inhibitors for metabolic and fibrotic diseases, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference with a fireside chat scheduled on May 19, 2026. The event will be webcast and archived for investors and me…
OIO Group announced it has entered into a term sheet for the proposed acquisition of a privately held German automotive engineering and low-volume production platform. The acquisition aims to strengthen OIO's engineering depth, prototype capability, and operational infrastructure in Europe, supporting the ongoing development and production of the D…
Can-Fite BioPharma Ltd. announced advancement of its pancreatic cancer drug Namodenoson into a Phase 2b study combining it with immunotherapy. This follows encouraging Phase 2a data showing favorable safety and clinical activity in advanced pancreatic adenocarcinoma patients. The company plans to discuss study design and partnership negotiations at…
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focusing on oncology and obesity therapies, disclosed that CEO Yuval Cohen will present at both the RBC Capital Markets and Jefferies Global Healthcare Conferences in May and June 2026, respectively. These presentations aim to update investors on company progress, including their pip…
Victoria’s Secret & Co. invites investors and analysts to listen to its Q1 2026 earnings webcast on June 2 at 8:30 a.m. ET, with the related financial release anticipated approximately one hour prior. The company operates globally with leading brands including Victoria’s Secret, PINK, and Adore Me, and provides a detailed safe harbor statement high…
Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation therapies, announced that CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference and the Jefferies Global Healthcare Conference in May and June 2026. These events are opportunities for Nurix to present …
